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Asbtract
To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a
simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to
2017, 162 patients were treated with IMRTwith SIB to the prostate. IMRT plans were designed to deliver 50.4Gy in 28 fractions
(1.8 Gy/fraction) to the pelvic lymph nodes (whole pelvis radiotherapy, WPRT) while simultaneously delivering 57.4 Gy in 28
fractions (2.05 Gy/fraction) to the seminal vesicles and 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate for high risk
patients. For intermediate risk patients the same technique was applied, without WPRT. Acute and cumulative late genitourinary
(GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) scoring
system. Of the 162 patients enrolled, 156 (96%) completed the treatment as planned. The median follow-up time was 30 months.
Seventy-eight patients (48.2%) were treated with WPRT. The rate of acute grade ≥ 2 GI and GU toxicities in all patients were
22% and 58%, respectively. The rate of cumulative late grade ≥ 2 GI and GU toxicities were 11% and 17%, respectively. Acute
grade 3 GI and GU toxicities occurred in 1% and 1%. Late grade 3 GI and GU side effects occurred in 5% and 4%, respectively.
None of the patients developed grade ≥ 4 toxicity. IMRTwith SIB technique using moderate hypofractionation to the prostate is
feasible treatment option for intermediate and high risk patients, associated with low rate of severe GU and GI toxicities.
Keywords Prostate cancer . Simultaneous integrated boost . Moderate hypofractionation . Intensity-modulated radiotherapy .
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Introduction
Several randomized trials have shown improved biochemical
control with dose escalation for prostate cancer [1–3]. The α/
β ratio for prostate cancer is suggested to be lower than that of
surrounding normal tissues, and may be as low as 1.5Gy [4,
5]. According to this, the therapeutic outcome using external
beam radiotherapy is expected to be improved with
hypofractionation, in case of delivering higher biologically
effective dose (BED) than with conventional external beam
radiotherapy. Asα/β ratio for rectum and urinary bladder is
estimated to be 3Gy and 5-10Gy, respectively, the low α/β
ratio ofprostate cancer theoretically allows dose escalation
with hypofractionation without increasing late toxicity [6].
Beyond the advantages in terms of tumour control and late
toxicity, the use of large dose per fraction is preferred by
patients and may have important implications for cost-
effectiveness by shortening the overall treatment time.
Several contemporary phase III, randomized trials with ma-
ture data have confirmed similar tumour control and late tox-
icity among various hypofractionated regimens to convention-
ally fractionated external beam radiotherapy [7].
Independently of the patients risk groups, except one trial,
the treatment target volume was the prostate gland and ±
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seminal vesicles without pelvic lymph nodes. The rational of
elective whole pelvis radiotherapy (WPRT) in patients with
high risk of subclinical lymph node involvement (Roach equa-
tion ≥15%) is the possibility to improve loco-regional control
[8]. In these high risk patients, surgical series with extended
lymphadenectomy showed a considerable incidence (17–
46%) of microscopic disease in the pelvic lymph nodes
[9–13]. Large, contemporary retrospective trials confirmed a
statistically significant benefit in biochemical control with
WPRTcompared to prostate (± irradiation of seminal vesicles)
irradiation, only [14–19]. However, currently there is insuffi-
cient evidence to recommend routine use of WPRT for high
risk patients. Three randomized trials have shown no benefits
for WPRTwith respect to disease-free survival or overall sur-
vival [20–22]. Since 2015 we have treated intermediate and
high risk prostate cancer patients with image-guided, intensity
modulated radiotherapy (IG-IMRT), using a simultaneous in-
tegrated boost (SIB) to the prostate for moderate
hypofractionation. The aim of this phase II study was to eval-
uate the acute and late side effects after moderate
hypofractionation with or without WPRT in combination with
SIB technique to the prostate.
Materials and Methods
This prospective study was approved by our institutional eth-
ical review board (68.2019). Patients with less than 12months
of follow up were excluded from the analysis. The main char-
acteristics of the patients are shown in Table 1. Between
January 2015 andMarch 2017, 162 patients with histological-
ly confirmed adenocarcinoma of the prostate were enrolled in
this trial. Before treatment a detailed medical history was re-
corded and physical examination including digital rectal ex-
amination was performed. A pretreatment bone scan and ab-
dominal CTor MRI were required to stage the prostate cancer
and to exclude distant metastases. Patients with prior pelvic
irradiation, a history of collagen vascular or inflammatory
bowel disease were also excluded. In accordance with
D’Amico et al. [23], four risk groups were identified: low risk:
≤cT2a and Gleason score ≤ 6 andPSA <10 ng/mL; intermedi-
ate risk: cT2b and/orGleason score 7and/or PSA10–20 ng/ml;
high risk: ≥cT2c and/or Gleason score ≥ 8 and/or PSA >
20 ng/mL and/or patients with cN1 disease. All patients par-
ticipating in this study were intermediate or high risk or node
positive. High risk and node positive patients received whole
pelvic irradiation. According to our institutional protocol in
high risk patients older than 70 years, considering the toxicity/
benefit ratio, prophylactic WPRT was not performed, in the
lack of high level of evidence proving better biochemical con-
trol or disease free survival after WPRT. Intermediate risk
patients with bulky disease or unfavourable histological pa-
rameters received neoadjuvant and concomitant hormone
therapy for 6 months (short-term hormone therapy). In high
risk patients neoadjuvant-concomitant-adjuvant hormone
therapy was given for 24–36 months (long-term hormone
therapy). For patient immobilization supine or prone position
is recommended [24]. In this study planning computed to-
mography (CT) imaging was performed in supine position
using knee and ankle fixation support system for immo-
bilization of the legs. Patients arms laid on their chest.
Axial images were obtained with 3–5 mm slice thickness
from L1 vertebra to about 3 cm below the ischial tuber-
osities. Before planning CT, patients were instructed to
have moderately,comfortablyfilled bladder by drinking
0.5 l of water (after having it emptied) half an hour prior
to CT and an emptyrectum. In case of habitual constipa-
tion light laxative was recommended. Four tattoos were
marked on the skin at the time of planning CT.
The rectum, bladder and hip joints were contoured as or-
gans at risk (OARs). For intermediate risk 2 clinical target

























High or lymph node positive 128 (79%)
Hormonal therapy
No 16 (10%)
Short (≤ 6 months) 24 (15%)
Long (> 6 months) 122 (75%)
1 TURP: transurethral resection of the prostate; 2 EBRT: external beam
radiotherapy
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volumes were defined. The prostate clinical target volume
(CTV_pros) included the whole prostate gland. The prostate
and seminal vesicles CTV (CTV_psv) was generated by 5mm
expansion of CTV_pros in all directions except posteriorly at
the prostate-rectum interface + proximal 1 cm of the seminal
vesicles.
For high risk patients CTV_pros was the same as above.
CTV_psv was defined by 5 mm expansion of CTV_pros in all
directions except posteriorly + proximal 2 cm of seminal ves-
icles (in case of cT3b the entire seminal vesicles were includ-
ed). Whole pelvis clinical target volume (CTV_pelv)
consisted of CTV_psv + common iliac (under L5-S1 space),
external iliac, presacral and obturator lymph nodes [25].
CTV_psv margins around CTV_pros were defined according
to Chao et al. [26]. After analyzing a large number of prosta-
tectomy specimens they found ≥4 mm extra capsular exten-
sion in 13% and 19% of the specimens in intermediate and
high risk disease respectively.
Image guidance was performed using fiducial markers
when pelvic irradiation was not required and with mega- or
kilovoltage cone beam CT (MV or KV CBCT) in case of
WPRT. During the whole treatment course daily orthogonal
kilovoltage portal images were performed and fiducial
markers were used for verification and online correctionof
patients’ setup. In the WPRT group or in the cases of lacking
fiducials CBCT and online correctionof patients’ setup was
performed before the first 3 fractions. After the systematic
error was calculated, isocentre was modified to exclude the
systematic error, and thereafter CBCT based IGRT was used
weekly for the rest of treatment. According to our institutional
analysis, PTV margins with the use of fiducial and CBCT
were 5 mm and 8 mm in every direction respectively.
All patients were treatedin 28 fractions with Bstep and
shoot^ IMRT or Volumetric Modulated Arc Therapy
(VMAT) using 6–10 MV photon beams from Artiste
(Siemens Medical Solutions Inc., USA) or TrueBeam and
VitalBeam (Varian Medical Systems, Palo Alto, USA) linear
accelerators, respectively.
Intermediated risk patients received 70 Gy to PTV_pros in
2.5Gy/fraction (EQD2 = 80 Gy) and 57.4 Gyto PTV_psv in
2.05 Gy/fraction (EQD2 = 58.2 Gy). High risk and lymph
node positive patients received 70 Gy to PTV_pros, 57.4Gy
to PTV_psv and 50.4 Gy to the pelvic lymph nodesusing
1.8 Gy/fraction. For PTV coverage, the 95% of the prescribed
dose was requested to cover 95% of the target volume
(V95% > 95%) for all PTVs. Rectum V45Gy, V63Gy, bladder
V45Gy, hip joints V45Gywas constrained below 50%, 20%,
65% and 10% of their volumes respectively. Dose constraint
was not used regarding the small bowels. In Fig. 1 dose dis-
tribution is shown for the three target volumes in a high risk
prostate cancer patient.
Patients were evaluatedevery second week during the treat-
ment, every three months after radiation therapy for the first
year and every 6 months thereafter. Acute and late genitouri-
nary (GU) and gastrointestinal (GI) toxicities were scored ac-
cording to the Radiation Therapy Oncology Group (RTOG)
scoring system. Acute toxicities were reported during radia-
tion therapy or within the initial 3-month follow-up.
Biochemical relapse free survival (bRFS) and cancer spe-
cific survival (CSS) curves were calculated using the Kaplan-
Meier method. Spearman rank order and Chi-squared tests
were used to evaluate the correlations between pelvic irradia-
tion, method of image guidance, transurethral resection of
prostate (TURP), hormone therapy, different dosimetric pa-
rameters of rectum, bladder, hip joints and acute GI, GU tox-
icities. Kaplan-Meier method and Gehan-Wilcoxon tests were
used to evaluate the effects of pelvic irradiation, method of
image guidance, TURP, hormone therapy on toxicity free sur-
vival. Logistic linear and Cox regressions were used in mul-
tivariate analysis to evaluate the prognostic factors of acute
and late toxicities.
Results
Of 162 patients 156 (96%) completed the moderately
hypofractionated radiotherapy with SIB technique as planned.
Seventy-eight patients (48.2%) were treated with WPRT, 84
patients (51,8%) with no WPRT. Six patients due to their age
(74-82 year) and acute GU or GI grade 2 side effects received
only 27 fractions (67.5 Gy to the prostate in 2.5 Gy fractions).
Median follow-up was 30 months (range: 21–45).
The dosimetric data of the treatment plans are detailed in
Table 2.Our dose constrains for rectum and hip joints have
been reached in every patient. In 7 patients (4.3%) bladder
V45 was >65% because of their relatively empty bladder at
time of planning CT. Due to pre-treatment urinary symptoms
these patients could not achieve filled bladder. IGRTwas per-
formed with fiducial markers, kV CBCT or MV CBCT in
32.7%, 61.1% and 6.2% of the patients, respectively.BStep
and shoot^ IMRT and VMAT techniques were applied in
6.2% and 93.8% of patients, respectively.
Acute and late toxicities are reported in Table 3.In general,
urinary toxicity resolved spontaneously or with the adminis-
trat ion of non-steroidal anti- inflammatory or α1
blockermedications. Six patients (4%) presented grade 3 late
GU toxicity and 8patients (5%) grade 3 late GI toxicity. None
of the patients experienced acute or late grade 4 side effects.
We found no correlation between acute or late toxicity
andthe use of WPRT, previous urological surgery or modality
of IGRT.
Crude rate of biochemicalrelapse free survival and cancer
specific survival was 98% and 99%, respectively (Figs. 2 and
3). No in-field lymph node recurrence was observed.
Three patients (2%) developed multiplex bone metastases,
currently one of them is receiving chemotherapy, 2 patients
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(1%) died due to disease progression. Six (4%) patients died
from non-prostate cancer disease.
No correlation was found between WPRT vs. no WPRT,
method of image guidance, TURP vs. no TURP, length of
hormone therapy or the different dosimetric parameters of
rectum, bladder, hip joints and acute GI, GU toxicities.
Significant correlation was found between acute GI and acute
GU toxicities, between acute GI and cumulative late GI and
between acute GU and cumulative late GU toxicities
(p < 0.05).
With Gehan-Wilcoxon test only a non-significant trend
was observed for late GI toxicities in favour of image guid-
ance with gold markers compared to CBCT based methods.
For other parameters significant effects on toxicity were not
found. In multivariate analysis no significant predictor was
found for acute or late GI or GU toxicities.
Discussion
Based on the radiobiological assumption that prostate cancer
has a high sensitivity to fraction dose, due to a low α/β ratio
(1.5Gy), several randomized trials were published, using a
superiority (Regina Elena, Fox Chase, MD Anderson,
HYPRO) and non-inferiority (NRG Oncology, CHHiP,
PROFIT) design to compare moderate hypofractionation
(dose per fraction 2.4–3.5 Gy) to conventional fractionation
(dose per fraction 1.8–2 Gy) [27–35]. Both in superiority and
non-inferiority trials the rate of late toxicity was similar with
moderate hypofractionation compared to conventional frac-
tionation provided that the dose per fraction was kept below
3 Gy. However, only in one of these trials (Fox Chase trial) the
high risk patients were treated with WPRT. In this superiority
randomized trial 303 patients received either 76 Gy in 2 Gy/
fraction over 7.5 weeks or 70.2 Gy in 2.7 Gy/fraction while
the pelvis was treated up to 56 Gy in 38 fractions in the con-
ventional arm and up to 50 Gy in 26 fractions in the
hypofractionated group. GI grade 3 toxicities occurred in 2%
in both treatment arms, while GU grade 3 toxicities were
observed in 3.3% and in 4%, respectively.
In high risk prostate cancer there is still considerable con-
troversy in the literature regarding the role of elective pelvic
Fig. 1 Representative dose distributions of a VMAT plan for high risk prostate cancer patient with whole pelvis irradiation in axial, sagittal, coronal and
3D views
Table 2 Dose constraints and dosimetric parameters of organs at risk
Dosimetric parameter Dose constraint (%) Mean % (range)
Rectum V45Gy 50 29.8 (11–49)
Rectum V63Gy 20 9.5 (2–19)
Bladder V45Gy 65 36.4 (0.1–80)
Hip joints V45Gy 10 1.3 (0.1–9)
Table 3 Acute and cumulative late toxicities
Toxicity Grade Acute toxicity
(%) N = 162
Late toxicity
(%) N = 162
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node irradiation. In these patients there is a high probability of
occult, radiologically undetectable lymph nodemetastases [8].
Based on the results of a randomized, phase III study compar-
ing prostate only radiation therapy with WPRT, a trend to
increased progression free survival was demonstrated in the
group of patients with >15% probability of lymph node me-
tastasis treated with WPRT [36, 37]. Another open issue
regardingWPRT is the potential increase of toxicity, because
of the larger irradiated volume compared to prostate only ra-
diotherapy. Recently, several trials reported reduction of GI
side effects using IMRT for irradiation of the pelvic lymph
nodes [37, 38]. In the current trial none of the patient experi-
enced grade 4 toxicity. Of 162 patients 2 (1%) developed acute
GI and GU grade 3 side effects, late GI and GU grade 3
toxicities occurred in 8 (5%) and 6 (4%) patients, respectively.
Di Muzio et al. [39, 40] recently published their 5-year
results of moderately hypofractionated radiation therapy with
SIB to the prostate. Intermediate and high risk patients re-
ceived 51.8Gy to pelvic nodes and concomitant SIB to the
prostate up to 74.2 Gy in 28 fractions. Low risk patients were
treated to the prostate only with 71.4Gy in 28 fractions.
Among 211 patients the incidence of acute GU grade 2 and
grade 3 toxicity was 29% and 1.9%, respectively, GI grade 2
and grade 3 toxicity occurred in 6.2% and 0.5%, respectively.
Late GU grade ≥2 and grade ≥ 3 toxicity was 20.2% and 5.9%,
late GI grade ≥2 and grade ≥ 3 toxicity 17% and 6.3% respec-
tively. One patient experienced grade 4 toxicity (cystectomy).
Saracino et al. [41] reported 5-year results in 110 high risk
patients treated with WPRT and SIB to the prostate. The 3-
and 5-year rate of grade ≥ 2 late GI toxicity was 2% and 5%,
respectively, while the 3- and 5-year rate of grade ≥ 2 late GU
toxicity was 5% and 12%, respectively. The rate of grade 2
acute rectal, intestinal and genitourinary toxicities were 40%,
23%, and 39%, respectively, and none of the patients experi-
enced grade 3 toxicity [42].
Franzese et al. [43] reported the results of 90 high risk pa-
tients treated with moderately hypofractionated radiotherapy
with SIB. At 25 months late grade 2 and 3 GI toxicitywas
observed in 1% and 0%, respectively. The rates of developing
any late GU grade 2 or 3 toxicity were 6% and 1%, respectively.
The results of other important trials usingWPRTcombined
with SIB to the prostate areshown in Table 4.
In our prospective study with large number of patients, the
toxicity rates compare favourably with similar trials using
WPRT with SIB to the prostate. Despite the fact that in
WPRT group the irradiated volume was larger compared to
noWPRT group, no correlation was found betweenWPRT vs.
no WPRT and acute GI, GU toxicities. To our opinion, the
improved dose distribution of IMRT plans allowing a reduced
dose bath to the rectum and the accurate IGRT techniques may
Fig. 2 Time to biochemical failure
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Fig. 3 Time to prostate cancer death
Table 4 Results of clinical trials using whole pelvis radiation therapy (WPRT) combined with simultaneous integrated boost (SIB) to the prostate. SV:
seminal vesicles
Reference No. patients Total dose/fraction
dose (Gy)
No. fractions Median follow-up
(months)
Acute toxicity
grade ≥ 3 (%)
Late toxicity
grade ≥ 3 (%)
Biochemical
control (%)
GU GI GU GI
McCammon, 2008 [44] 30 pelvis: 50.4/1,8 28 24 0 3.3 0 10 –
prostate: 70/2.5
Engels, 2009 [45] 28 pelvis: 54/1.8 30 10 4 0 – – –
prostate: 70.5/2.35
Adkison, 2010 [46] 53 pelvis: 56/2 28 25 0 0 2 0 81
prostate: 70/2.5
Alongi, 2012 [47] 70 pelvis: 51.8/1.85 28 11 1 0 – – –
prostate: 74.2/2.65
Pollack, 2013 [28] 303 pelvis: 50/1.92 26 68 – – 4 2 76.7
prostate: 70.2/2.7
Saracino, 2014 [41] 37 pelvis: 57/1.56 40 56 0 0 0 0 90
prostate: 80/2
Di Muzio, 2016 [40] 211 pelvis: 51.8/1.85 28 60 1.9 0.5 5.9 6.3 95
prostate: 74.2/2.65
Franzese, 2017 [43] 90 pelvis: 51.8/1.8 28 25 2 0 1 0 90
SV: 65.5/2.34
prostate: 74.2/2.65
Chang, 2017 [48] 55 pelvis: 50.4/1.68 30 24 – – 6 2 96
SV: 54/1.8
prostate: 72/2.4
Magli, 2017 [49] 41 pelvis: 50/2 25 60 0 0 0 0 95
SV: 56.25/2.25
prostate: 67.5/2.7
Present study 162 pelvis: 50.4/1.8 28 30 1 1 4 5 98
SV: 57.4/2.05
prostate: 70/2.5
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be the explanation of the finding above. Another result of our
trial is that treatment side effects did not correlate with IGRT
regimens (fiducial, kV CBCT or MV CBCT).
At 30-month follow-up time we experienced excellent bio-
chemical control (98%).
There are several limitations of our study. One is the relatively
short follow-up time. Longer follow-up is necessary to evaluate
long-term toxicity and biochemical control. Another limitation is
the lack of patient-reported toxicity,therefore we may underesti-
mate the toxicity rates. Furthermore, this study was not a ran-
domized one.We did not compareour SIB treatment protocol to a
conventionally fractionated treatment schedule.
Conclusion
WPRTwith SIB tothe prostate, seminal vesicles or positive pel-
vic lymph nodes is a feasible and safe technique for patientswith
intermediate and high risk localized, locally advanced and node
positiveprostate cancer. According to our results this treatment
seems to be associated with a tolerable frequency and severity of
acute GU and GI toxicities. The rate of severe late GI and UG
toxicities are low and comparable to rates with conventionally
fractionated treatments. This technique provides shorter overall
treatment time compared to conventional fractionation thus spar-
ing treatment capacity on the linear accelerator. Additional vali-
dation with a longer follow-up is needed.
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